Consensus EPS · Q2 2026
$1.28
Consensus revenue · Q2 2026
$12.5B
Analysts
15
Expected report
Jul 16, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 15 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $12.2B | $12.5B | $12.7B |
| EPS | $1.26 | $1.28 | $1.29 |
| EBITDA | $3.3B | $3.3B | $3.4B |
| EBIT | $2.3B | $2.4B | $2.4B |
| Net income | $2.2B | $2.2B | $2.3B |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $11.2B | $11B | +1.5% | $1.15 | $1.14 | +0.5% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Abbott Laboratories (ABT) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 2 analysts.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $92.00 | $121.25 | $120.50 | $145.00 | $94.40 | +28.4% |
Upside calculated vs most recent trading price of $94.40.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 41 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 22, 2026 | Piper Sandler | maintain | Overweight | Overweight |
| Apr 27, 2026 | BTIG | maintain | Buy | Buy |
| Apr 20, 2026 | Barclays | maintain | Overweight | Overweight |
| Apr 17, 2026 | Stifel | maintain | Buy | Buy |
| Apr 17, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Apr 17, 2026 | Piper Sandler | maintain | Overweight | Overweight |
| Apr 17, 2026 | Oppenheimer | maintain | Outperform | Outperform |
| Apr 17, 2026 | Evercore ISI Group | maintain | Outperform | Outperform |
| Apr 17, 2026 | BTIG | maintain | Buy | Buy |
| Apr 17, 2026 | Benchmark | maintain | Buy | Buy |
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation